Akno Biopharmaceuticals

Akno Biopharmaceuticals is a clinical-stage biotechnology company focused on developing innovative topical treatments for dermatological conditions, specifically acne vulgaris. The company's lead candidate, AKN-022, is a first-in-class topical small molecule inhibitor of Acetyl-CoA carboxylase (ACC), an enzyme that plays a critical role in sebum production. By inhibiting ACC, AKN-022 aims to reduce the excessive oil production that drives acne formation without the systemic side effects associated with oral treatments. Headquartered in Israel, Akno Biopharmaceuticals leverages its expertise in lipid metabolism to create targeted therapies for high-unmet-need skin disorders.